NeoCremar has initiated a preclinical study to validate the veterinary functional efficacy of its galacto-oligosaccharide ingredient, NeoGOS-P70.
This study, scheduled to run for approximately six months, will evaluate the potential of NeoGOS-P70 to improve gut health and skin barrier function in healthy companion dogs. The research will be conducted by Limpid Inc., a specialized veterinary clinical research organization, and will ensure scientific credibility through research advisory from the College of Veterinary Medicine at Seoul National University.
Through this study, NeoCremar aims to verify the potential application of NeoGOS-P70 in the companion animal sector and secure foundational data for future business expansion into the pet food and supplement markets. Furthermore, the company plans to pursue publication in international peer-reviewed journals based on the study findings.
We will continue to secure scientific evidence for our functional ingredients and expand the applicability of NeoGOS-P70 across diverse sectors.